Henry Ji, PhDChairman, interim CEO for ARK, full time CEO for Sorrento
Henry is the co-founder and has served as a director of Sorrento Therapeutics since January 2006. Dr. Ji served as Sorrento’s Chief Scientific Officer before becoming the Chief Executive Officer in 2011. He has experience in scientific endeavors as well as business development. Henry obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Henry has a dog and has spent a lot of money in veterinary care (surgeries) over the years!
Alexis Nahama, DVMPresident for Ark Animal Health
Alexis is President for Ark Animal Health since the beginning of 2017. Former Head of Marketing for VCA Animal Hospitals, a publicly traded $1.7B in revenue company that owns and operates over 600 veterinary hospitals across North America, that sold to Mars Incorporated for about $7.2B. Dr Nahama is a 1995 graduate from the Maisons-Alfort Veterinary School (Paris, France). His broad career experience includes pharmaceutical/biotech research & development/stem cell therapy drug development, as well as 22 years marketing global animal health products and services to professionals and consumers. Alexis also serves on the board for the Catalyst council (an evidence-based Not for Profit Corporation dedicated to improving care provided to cats). Alexis enjoys the companionship of a mostly healthy (but allergy and pancreatitis prone) Havenese dog and recently lost his cat to renal disease.
Dean FerrignoInterim CFO for ARK, full time Chief Accounting Officer for Sorrento
Dean is Chief Accounting Officer for Sorrento Therapeutics where he heads the finance, accounting and investor relations functions. Mr. Ferrigno has spent the last 15 years in Pharmaceutical and Research companies. Most recently from 2015 through November 2016, he served as Vice President, Finance of Scilex Pharmaceuticals Inc., of which Sorrento acquired a majority stake in November 2016. While at Scilex he was leading Accounting and Finance, supporting the planned commercial launch of ZTLido and Business Development activities. Mr. Ferrigno also held senior financial roles including the Cancer Trials Network of Texas in 2011 through 2013 as VP of Finance and Chief Financial Officer for the Sarah Cannon Research Institute in 2010. Prior to that he was Senior Director of Finance with Daiichi Sankyo Research & Development from 2002 through 2009. Mr. Ferrigno holds an MBA in Corporate Finance from Fairleigh Dickinson University and is a licensed CPA. Dean had a bulldog that he misses dearly.
George NgCorporate Secretary, Interim General Counsel for ARK, full time Chief Administrative Officer and Chief Legal Officer for Sorrento
George heads the legal, human resources, compliance and intellectual property functions at Sorrento Therapeutics. Prior to joining Sorrento, Mr. Ng held various senior management positions with publicly-traded, global biotechnology and pharmaceutical companies, including BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). George is also a past President-Elect of the Pan Asian Lawyers of San Diego (PALSD) and was previously appointed to the Leadership Development Committee of the Wake County Bar Association in North Carolina. He is a frequent speaker and noted authority on legal, compliance and business issues in the life sciences, with past speaking engagements at the 2011 BIO International Convention and various pharmaceutical congresses and conferences. He obtained his J.D. from the University of Notre Dame and a B.A.S. (dual degree) in Biochemistry and Economics from the University of California, Davis. George enjoys sharing time with his family’s chinchilla (Poofy) when home.
Mark R. Brunswick, PhDInterim Regulatory Affairs for ARK. VP, Head of Regulatory Affairs, Sorrento
Mark has over 35 years of experience in Regulated Industry including over 9 years in the US FDA, Center for Biologics, Division of Monoclonal Antibodies. Most recently, Dr Brunswick was Head of Regulatory Affairs and Quality at Sophiris Bio, a company developing a drug for benign prostatic hyperplasia and prostate cancer. Prior to that he was head of Regulatory Affairs at Arena Pharmaceuticals, a company specializing in therapies directed at G Protein receptors and also led the regulatory group at Elan Pharmaceuticals concentrating on Alzheimer Disease and the pain compound, ziconotide. He obtained his Ph.D. from University College London, University of London.